Skip to main content

Table 4 Association of plasma biomarkers with the expression levels of APH1B and their different levels between AD, MCI, and CN in AddNeuroMed

From: Dysregulated expression levels of APH1B in peripheral blood are associated with brain atrophy and amyloid-β deposition in Alzheimer’s disease

Protein TAPH1B PAPH1B TMCI PMCI TAD PAD
Neuropilin-1 3.95 9.69 × 10−5 − 0.0657 9.48 × 10− 1 0.845 3.99 × 10− 1
Tropomyosin receptor kinase A 3.76 2.00 × 10−4 − 0.571 5.68 × 10− 1 1.54 1.24 × 10− 1
Growth hormone receptor −3.59 3.80 × 10− 4 − 2.44 1.51 × 10− 2 − 3.25 1.29 × 10− 3
Apolipoprotein A1 − 3.53 4.82 × 10− 4 −0.448 6.54 × 10− 1 − 1.09 2.78 × 10− 1
  1. Data for 344 participants were unavailable. TAPH1B and PAPH1B values were obtained from linear regression analysis for the expression levels of APH1B with adjustment of age and sex. Results with uncorrected P < 0.001 are presented. TMCI, TAD, PMCI, and PAD were obtained from analysis of covariance for diagnosis group (CN, MCI, and AD) with adjustment of age and sex
  2. Abbreviations: AD Alzheimer’s disease; CN cognitively normal older adults; MCI mild cognitive impairment; PAPH1B P-value for APH1B expression in linear regression analysis; PAD P-value for AD diagnosis in the analysis of covariance; PMCI P-value for MCI diagnosis in the analysis of covariance; TAPH1B T-value for APH1B expression in linear regression analysis; TAD T-value for AD diagnosis in the analysis of covariance; TMCI T-value for MCI diagnosis in the analysis of covariance